{"schema_version":"secwatch.filing_event.v1","accession":"0001323885-22-000008","form_type":"8-K","ticker":"ATRC","cik":"0001323885","company_name":"AtriCure, Inc.","filed_at":"2022-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.917168+00:00","generated_at":"2026-06-27T07:53:03.699995+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AtriCure Q4 revenue $73.2M (+26.8% YoY); guides FY22 rev $315-330M","bullets":["Q4 2021 revenue $73.2M (+26.8% YoY); U.S. $61.2M (+29.1%), Intl $12.0M (+16.3%).","FY2021 revenue $274.3M (+32.8%); GAAP net income $1.11/shr; adj loss per share $1.16.","FY2021 includes $184.8M credit for contingent consideration change and $82.3M IPR&D impairment.","FY2022 revenue guidance $315-330M (15-20% growth); adj EBITDA loss $2-4M; adj loss/shr $1.07-1.12.","Milestones: Hybrid Therapy FDA approval, ENCOMPASS 510(k), Cryo Nerve Block expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001323885-22-000008","json":"https://secwatch.observer/filing/0001323885-22-000008.json","markdown":"https://secwatch.observer/filing/0001323885-22-000008.md","text":"https://secwatch.observer/filing/0001323885-22-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1323885/000132388522000008/0001323885-22-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1323885/000132388522000008/atrc-20220215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T07:53:03.699995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}